Log in

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at BidaskClub

Last updated on Wednesday, August 5, 2020 | 2020 MarketBeat

Arbutus Biopharma (NASDAQ:ABUS) was downgraded by investment analysts at BidaskClub from a "buy" rating to a "hold" rating in a research note issued on Wednesday, BidAskClub reports.

Several other research firms have also recently weighed in on ABUS. Chardan Capital reaffirmed a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research report on Wednesday, May 13th. Robert W. Baird cut Arbutus Biopharma from an "outperform" rating to a "neutral" rating in a research report on Friday, July 24th. B. Riley upped their price objective on Arbutus Biopharma from $6.00 to $8.00 in a research report on Monday, July 27th. JMP Securities initiated coverage on Arbutus Biopharma in a research report on Monday, July 27th. They set an "outperform" rating and a $8.00 price objective for the company. Finally, Wedbush raised Arbutus Biopharma from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $2.00 to $4.00 in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of "Hold" and an average price target of $5.63.

NASDAQ:ABUS opened at $3.75 on Wednesday. Arbutus Biopharma has a 1 year low of $0.82 and a 1 year high of $9.02. The stock has a market cap of $264.12 million, a price-to-earnings ratio of -1.40 and a beta of 3.25. The stock has a 50-day moving average price of $2.60 and a two-hundred day moving average price of $2.25.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.81 million. As a group, equities analysts expect that Arbutus Biopharma will post -0.87 earnings per share for the current year.

In related news, insider Michael J. Mcelhaugh sold 20,000 shares of the company's stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $5.01, for a total transaction of $100,200.00. Following the sale, the insider now owns 1,367,457 shares in the company, valued at $6,850,959.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company's stock.

Large investors have recently added to or reduced their stakes in the business. Spark Investment Management LLC bought a new stake in Arbutus Biopharma in the first quarter valued at approximately $28,000. Wedbush Securities Inc. bought a new stake in Arbutus Biopharma in the first quarter valued at approximately $43,000. Squarepoint Ops LLC bought a new stake in Arbutus Biopharma in the first quarter valued at approximately $43,000. Creative Planning bought a new stake in Arbutus Biopharma in the second quarter valued at approximately $60,000. Finally, Jane Street Group LLC bought a new stake in Arbutus Biopharma in the first quarter valued at approximately $73,000. Hedge funds and other institutional investors own 38.12% of the company's stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Read More: How Buying a Call Option Works

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

7 Stocks That Aggressive Investors Can Buy Now

There’s nothing like a steep market correction to test the risk appetite of even the most seasoned investor. With many investors seeing their 401k’s down 25%, 30% or more, it’s not surprising that many investors are taking money off the table.

And even during the most bullish market conditions, keeping some powder dry is a prudent decision.

But if you have an above-average risk appetite, then sitting on the sidelines is not your cup of tea. If you’re an investor with above-average risk tolerance, there are some opportunities to profit in this market. But you have to be looking in the right places.

At this time, the small-cap sector offers some interesting choices. Small-cap stocks are companies that have a market cap of less than $2 billion. Many of these stocks fall under the category of penny stocks, but that doesn’t make them bad. In some cases, they’re just obscure companies.

But right now, many investors will take growth wherever they can get it. And that’s why you should take a careful look at the 7 stocks we have in this presentation. The cost of entry is not high and the potential reward is worth your interest.

View the "7 Stocks That Aggressive Investors Can Buy Now".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.